MI-773 is primarily utilized in the field of cancer research, particularly in the study of p53 pathway reactivation. It functions as a potent and selective inhibitor of MDM2, a protein that negatively regulates the tumor suppressor p53. By inhibiting MDM2, MI-773 helps restore p53 activity, which can induce apoptosis in cancer cells. This makes it a valuable tool in preclinical studies aimed at developing new therapeutic strategies for cancers with wild-type p53. Researchers use MI-773 to explore its potential in enhancing the efficacy of chemotherapy and radiation treatments, as well as in understanding the mechanisms of p53-mediated tumor suppression. Its application is significant in advancing targeted cancer therapies and improving patient outcomes.